Drug intelligence / Profile preview

Allivra

Development stage: Unknown
Lead developer: PharmaS
Administration: Oral

Overview

**Allivra** is a PharmaS consumer-health dietary supplement marketed as lemon-flavored, direct-to-mouth oral powder sachets. Each sachet contains quail egg powder, zinc, and vitamin C. It is promoted for immune and antioxidant support and for alleviation of allergic-rhinitis symptoms, including symptoms associated with seasonal hypersensitivity. It is not an INN-assigned pharmaceutical medicine and no specific molecular target or pharmacologic mechanism has been established for the finished product.

Brand names: Allivra

Beyond the preview

Go deeper on Allivra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allivra.

Explore the full profile